InvestSMART

Anatara Lifesciences Ltd (ASX:ANR)

ALERT: Price-sensitive ASX Announcement for ANR
Current share price for ANR : $0.010 0.001 (11.11%)+
Announcement
Release
29 Apr 2026 5:08PM
Price at Release
$0.009
Full Release
download
Summary
Anatara Lifesciences Ltd, a company focused on developing evidence-based health products, provided a quarterly update for Q3 FY2026. Key activities included the completion of Mechanism of Action (MOA) assays for the Anti-Obesity Project, which showed promising but inconclusive results in weight management. The company plans a Phase 1 pharmacokinetic study for the AOC compound, classified as Generally Regarded As Safe. Anatara has $0.707 million in cash and is actively seeking business development opportunities. The GaRP Project continues with commercial interest in its gastrointestinal health applications. Cash outflows from operations were $0.327 million, and there remains a focus on strategic evaluations and potential mergers and acquisitions.
Key Points
  • Completion of MOA assays for the Anti-Obesity Project.
  • Plans for a Phase 1 pharmacokinetic study for compound AOC.
  • Current cash balance at $0.707 million.
  • Continued business development and strategic evaluations.
  • Ongoing interest in the GaRP Project for gastrointestinal health.
  • Net cash outflows from operations of $0.327 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.